Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05803200 · ClinicalTrials.gov registry record

A Study to Describe Mothers' and Babies' Outcomes After Exposure to HyQvia During Pregnancy

A clinical trial, sponsored by Takeda.

Completed
Registry status
7
Enrollment target

NCT05803200 is a clinical trial that has completed, run by Takeda. The registered enrollment target is 7 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05803200 has completed, sponsored by Takeda.

COMPLETED
Registry status
7 participants
Enrollment target

Study Summary

The main aim of this study is to provide further information on the safety profile of HyQvia during pregnancy. This will be done by checking the characteristics of the mother and their babies. They will also be checked for any safety outcomes that will occur when exposed to HyQvia during pregnancy.

Interventions

  • DRUG No intervention

Trial Details

FieldValue
Enrollment Target 7 participants
Start Date 2023-03-15
Est. Completion 2023-04-14

Sponsor

Takeda

408 total trials

What the Registry Record Tells You About NCT05803200

The ClinicalTrials.gov registry entry for NCT05803200 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which No intervention is the first listed.

NCT05803200 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT05803200 about?

NCT05803200 is a clinical study titled "A Study to Describe Mothers' and Babies' Outcomes After Exposure to HyQvia During Pregnancy". The main aim of this study is to provide further information on the safety profile of HyQvia during pregnancy. This will be done by checking the characteristics of the mother and their babies. They will also be checked for any safety outcomes that will occur when exposed to HyQvia during pregnancy.

What is the current status of trial NCT05803200?

This trial is currently completed. The enrollment target is 7 participants. The study started on 2023-03-15. Estimated completion is 2023-04-14.

What interventions are being tested in trial NCT05803200?

The interventions under investigation include: No intervention (DRUG).

Who is sponsoring clinical trial NCT05803200?

This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.